阻断肾素-血管紧张素系统对糖尿病大鼠肾脏血管紧张素Ⅱ及其受体表达的影响  

The effects of blocking renin-angiotensin system with losartan or perindopril on renal angiotensin Ⅱ and its type 1 receptor expression in STZ-induced diabetic rats

作　　者：张冬梅[1] 钟惠菊[1] 周敏[1] 

机构地区：[1]中南大学湘雅医院内分泌科,长沙410008

出　　处：《中华糖尿病杂志（1006-6187）》2005年第2期131-133,共3页

基　　金：湖南省科委课题基金(1013 42)

摘　　要：目的　探讨糖尿病大鼠血管紧张素Ⅱ(ATⅡ)及其AT1 受体(AT1R)表达的改变,以及阻断肾素血管紧张素系统(RAS)对其影响。　方法　将大鼠分成正常对照组(NC组)和糖尿病组(DM组)。糖尿病成模后4周,再将DM组分成培哚普利治疗组(DP组)、氯沙坦治疗组(DL组)和糖尿病对照组(DC组),共治疗12周。以放免法测定血浆ATⅡ(PA)及肾组织ATⅡ(RA),逆转录聚合酶链反应检测肾组织ATⅡ及AT1R表达。　结果　第4周时,DM组肾脏AT1R表达下降;第16周时,DC组PA、RA水平及AT1R表达较NC组显著增加,DP组和DL组RA水平及AT1R表达较DC组显著下降。　结论　糖尿病肾脏中存在ATⅡ及AT1R表达的异常;培哚普利和氯沙坦对糖尿病肾脏的保护作用可能与肾脏局部ATⅡ下降及AT1R表达的下调有关。Objective To observe the effects of blocking renin-angiotensin system with losartan or perindopril on renal angiotensinⅡand its type 1 receptor (AT_1R) expression in STZ-induced (diabetic) rats. Methods Male SD rats were randomly divided into 2 groups: normal control group (NC) and (diabetic) group. Diabetes was induced by STZ (65 mg/kg) abdominal injection. Four weeks later, diabetic rats were further divided into 4 groups: diabetic rats treated with losartan (DL, 20 mg·kg^(-1)·d^(-1)),diabetic rats treated with perindopril (DP,2 mg·kg^(-1)·d^(-1)) and diabetic untreated control group(DC). Radioimmunoassay was used to measure plasma and renal angiotensin (Ⅱ.)Expression of AT1R was detected by RT-PCR in each group before and after 12 week′s treatment. Results At the 4th week, renal AT_1R expression decreased. At the 16th week, plasma angiotensinⅡ,renal angiotensinⅡand AT_1R mRNA in diabetic untreated group were significantly higher than those in normal rats. (Renal) angiotensinⅡand AT_1R in losartan or perindopril-treatmented group were significantly lower than those in DC group. Conclusion Intrarenal RAS is abnormal in STZ-induced diabetic rats. Renoprotective effects of losartan and perindopril may partly induced by inhibiting renal angiotensinⅡ and AT_1R (expression.)

关 键 词：肾素-血管紧张素系统 糖尿病 大鼠 肾脏 血管紧张素Ⅱ 受体表达 ATⅡ 血流动力学 

分 类 号：R587.2[医药卫生—内分泌]